Dafinchi AI

ESPR

Healthcare

Cash and cash equivalents ended at $86.1 million, supporting the company’s path to sustainable profitability.
Collaboration revenue decreased 7% year-over-year to $42.1 million, impacted by a prior settlement milestone but grew 105% excluding that milestone.
Esperion achieved its first quarter of operating income from ongoing business of approximately $15 million.
Esperion reported total revenue of $82.4 million for Q2 2025, a 12% increase year-over-year despite a $25 million milestone payment in the prior year quarter.
Research and development expenses decreased 37% year-over-year to $7.2 million, and selling, general and administrative expenses decreased 11% to $39.5 million.
U.S. net product revenue grew 42% year-over-year to $40.3 million and increased 15% sequentially from Q1 2025.

KURA

Healthcare

As of June 30, 2025, Kura had $630.7 million in cash, cash equivalents, and short-term investments, down from $727.4 million at the end of 2024.
Cash runway is expected to fund operations into 2027, with additional collaboration milestones potentially extending resources.
General and administrative expenses rose to $25.2 million in Q2 2025 from $16.7 million in Q2 2024, mainly due to pre-commercial activities.
Kura reported collaboration revenue of $15.3 million in Q2 2025 from its Kyowa Kirin partnership, compared to no revenue in Q2 2024.
Net loss widened to $66.1 million in Q2 2025 from $50.8 million in Q2 2024, including noncash share-based compensation expense of $6.9 million.
R&D expenses increased to $62.8 million in Q2 2025 from $39.7 million in Q2 2024, driven by ziftomenib combination clinical trials.

PRCT

Healthcare

48 new HYDROS robotic systems were sold in Q2, with system revenue up 24% to $22.1 million.
Cash and equivalents stood at approximately $306 million as of June 30, 2025.
Gross margin expanded by 640 basis points to 65.4%, driven by operational efficiencies and higher average selling prices.
International revenue grew 69% to $9.6 million, driven by strong sales in the UK, Japan, and Korea.
Net loss improved to $19.6 million from $25.6 million, and adjusted EBITDA loss narrowed to $8 million from $18 million.
Operating expenses increased to $74 million from $58.3 million year-over-year.
Total revenue for Q2 2025 was $79.2 million, a 48% increase year-over-year.
U.S. revenue grew 46% to $69.6 million, with handpiece revenue up 58% and 12,750 handpieces sold, a 59% unit growth.

Earnings Feed